Art

J-GLOBAL ID：201802265890481388   Reference number：18A2175515

Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial

過去に治療を受けていない濾胞性リンパ腫患者でのオビヌツズマブの有効性と安全性:日本でのランダム化第III相GALLIUM試験に参加した患者のサブグループ解析

Author (27)： OHMACHI Ken (Tokai Univ., Kanagawa, JPN) ,  TOBINAI Kensei (National Cancer Center Hospital, Tokyo, JPN) ,  KINOSHITA Tomohiro (Aichi Cancer Center, Aichi, JPN) ,  ISHIKAWA Takayuki (Kobe City Medical Center General Hospital, Hyogo, JPN) ,  HATAKE Kiyohiko (Cancer Inst. Hospital, Tokyo, JPN) ,  ICHIKAWA Satoshi (Tohoku Univ. Graduate School of Medicine, Miyagi, JPN) ,  OHMINE Ken (Jichi Medical Univ., Tochigi, JPN) ,  KAMITSUJI Yuri (Matsushita Memorial Hospital, Osaka, JPN) ,  CHOI Ilseung (Kyushu Cancer Center, Fukuoka, JPN) ,  CHOU Takaaki (Niigata Cancer Center Hospital, Niigata, JPN) ,  TSUKASAKI Kunihiro (National Cancer Center Hospital East, Chiba, JPN) ,  KUMAGAI Kyoya (Chiba Cancer Center, Chiba, JPN) ,  TANIWAKI Masafumi (Kyoto Prefectural Univ. Medicine, Kyoto, JPN) ,  UCHIDA Toshiki (Japanese Red Cross Nagoya Daini Hospital, Aichi, JPN) ,  KIKUKAWA Yoshitaka (Kumamoto Univ. Graduate School of Medicine, Kumamoto, JPN) ,  KUBO Kohmei (Aomori Prefectural Central Hospital, Aomori, JPN) ,  MIHARA Keichiro (Hiroshima Univ. Hospital, Hiroshima, JPN) ,  TSUKAMOTO Norifumi (Gunma Univ. Graduate School of Medicine, Gunma, JPN) ,  IZUTSU Koji (Toranomon Hospital, Tokyo, JPN) ,  YOSHIDA Isao (Shikoku Cancer Center, Ehime, JPN) ,  ISHIDA Fumihiro (Shinshu Univ. School of Medicine, Nagano, JPN) ,  USUI Noriko (Jikei Univ. School of Medicine, Tokyo, JPN) ,  IIDA Shinsuke (Nagoya City Univ. Graduate School of Medical Sci., Aichi, JPN) ,  MURAYAMA Tohru (Hyogo Cancer Center, Hyogo, JPN) ,  UEDA Eisuke (Chugai Pharmaceutical Co., Ltd., Tokyo, JPN) ,  KURIKI Hiroshi (Chugai Pharmaceutical Co., Ltd., Tokyo, JPN) ,  ANDO Kiyoshi (Tokai Univ., Kanagawa, JPN)
Material： International Journal of Hematology  (Int J Hematol)
Volume： 108  Issue： 5  Page： 499-509  Publication year： Nov. 2018 
JST Material Number： F0888A  ISSN： 0925-5710  CODEN： IJHEEY  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： GALLIUM試験 ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A2175515&from=J-GLOBAL&jstjournalNo=F0888A") }}

JST classification (3)： Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Blood cell tumors(=neoplasms)  (GK04000M) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Reference (30)：

• Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725-32.
• Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417-23.
• Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25:1986-92.
• Salles G, Mounier N, de Guibert S, Morschhauser F, Doyen C, Rossi JF, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008;112:4824-31.
• Rituxan injection prescribing information. 2017. http://www.info.pmda.go.jp/downfiles/ph/PDF/380101_4291407A1027_2_23.pdf. Accessed June 2018.

Terms in the title (12)： 治療 ,  濾胞性リンパ腫 ,  患者 ,  オビヌツズマブ ,  有効性 ,  安全性 ,  日本 ,  ランダム化 ,  試験 ,  参加 ,  サブ ,  グループ解析